Drug Trial Radar · NCT06091579
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Sep 17, 2020
Primary completion
Jan 12, 2021
Study completion Jan 12, 2021
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety and tolerability of single and multiple doses of treprostinil palmitil inhalation powder in healthy participants.
Conditions
- Healthy Volunteers
Interventions
Treprostinil Palmitil Inhalation PowderDrug
Oral inhalation using a Plastiape capsule-based dry powder inhaler.
PlaceboDrug
Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Number of Participants who Experienced an Adverse Event (AE)Time frame: Up to Day 31 in Part A and Day 37 in Part B
Locations
1 site in 1 country. Site status is shown where the registry gives one.
USA001
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.